Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabatolimab plus hypomethylating agents in intermediate/high/very high risk MDS
NCT03946670Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2019
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing MBG453 + HMA with Placebo + HMA (2 arms). Primary endpoints: Complete Remission Rate at 7 months and Progression Free Survival at 32 months. Started Jun 2019; status: terminated.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03946670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946670.